Amodiaquine

Amodiaquine, also known as AQ or AQ-resistance, is an antimalarial drug used to treat and prevent malaria. It is a 4-aminoquinoline derivative that acts by disrupting the parasite’s hemoglobin metabolism, thereby inhibiting its replication within red blood cells. Amodiaquine is often used in combination with other antimalarial drugs due to the emergence of resistance against single-drug treatments.
Typically, Amodiaquine is administered as part of an Artemisinin-Based Combination Therapy (ACT) along with other antimalarials. This combination therapy is recommende. For uncomplicated Plasmodiu. Falciparum malaria, particularly in areas where there is a high risk of resistance to other antimalarial drugs. As a single agent, Amodiaquine is effective against P. Falciparum and P. Vivax, but its usage is limited due to the risk of severe gastrointestinal side effects.
The recommended dosage for Amodiaquine is 30mg/kg for children weighing less than 40 kg, and 10mg/kg for children weighing over 40 kg. For adults and children over 12 years, a standard dose is 1g (5 tablets of 200mg each) taken once or in divided doses over one to three days.
Side effects of Amodiaquine include gastrointestinal symptoms, such as nausea, vomiting, anorexia, and abdominal pain. In rare cases, hepatotoxicity and agranulocytosis may occur, necessitating close monitoring of the patients. Amodiaquine may also cause hypersensitivity reactions and should be used with caution in individuals with a history of hypersensitivity to other 4-aminoquinoline compounds.